MAP Pharmaceuticals should trade higher on FDA news, says JPMorgan

theflyonthewall.com

JPMorgan expects shares of MAP Pharmaceuticals to trade higher today after the company announced that the Levadex resubmission has been accepted by the FDA with a six-month review. The firm continues to expect approval for Levadex and maintains an Overweight rating on the stock.

View Comments